User:JonSDSUGrad/Sandbox/TEST7 TP53

From Wikipedia, the free encyclopedia


tumor protein p53 (Li-Fraumeni syndrome)
PDB rendering based on 1a1u.
Available structures: 1a1u, 1aie, 1c26, 1gzh, 1hs5, 1kzy, 1olg, 1olh, 1pes, 1pet, 1sae, 1saf, 1sag, 1sah, 1sai, 1saj, 1sak, 1sal, 1tsr, 1tup, 1uol, 1ycs, 2ac0, 2ady, 2ahi, 2ata, 2b3g, 2bim, 2bin, 2bio, 2bip, 2biq, 2fej, 2gs0, 2h1l, 2j1w, 2j1x, 2j1y, 2j1z, 2j20, 2j21, 2ocj, 3sak
Identifiers
Symbol(s) TP53; LFS1; TRP53; p53
External IDs OMIM: 191170 MGI: 98834 HomoloGene: 460
Orthologs
Human Mouse
Entrez 7157 22059
Ensembl ENSG00000141510 ENSMUSG00000059552
Uniprot P04637 n/a
Refseq NM_000546 (mRNA)
NP_000537 (protein)		 NM_011640 (mRNA)
NP_035770 (protein)
Location Chr 17: 7.51 - 7.53 Mb Chr 11: 69.4 - 69.41 Mb
Pubmed search [1] [2]

[edit] Summary

Tumor protein p53, a nuclear protein, plays an essential role in the regulation of cell cycle, specifically in the transition from G0 to G1. It is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing DNA-binding, oligomerization and transcription activation domains. It is postulated to bind as a tetramer to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome.[1]

[edit] References

  1. ^ Entrez Gene: TP53 tumor protein p53 (Li-Fraumeni syndrome). Retrieved on 2007-08-07.

[edit] Further reading

  • Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). "p53 mutations in human cancers.". Science (New York, N.Y.) 253 (5015): 49-53. PMID 1905840. 
  • Harris CC (1994). "p53: at the crossroads of molecular carcinogenesis and risk assessment.". Science (New York, N.Y.) 262 (5142): 1980-1. PMID 8266092. 
  • Giaccia AJ, Kastan MB (1998). "The complexity of p53 modulation: emerging patterns from divergent signals.". Genes & development 12 (19): 2973-83. PMID 9765199. 
  • Choi J, Donehower LA (1999). "p53 in embryonic development: maintaining a fine balance.". Cellular and molecular life sciences : CMLS 55 (1): 38-47. PMID 10065150. 
  • Jayaraman L, Prives C (1999). "Covalent and noncovalent modifiers of the p53 protein.". Cellular and molecular life sciences : CMLS 55 (1): 76-87. PMID 10065153. 
  • Shaul Y (2000). "c-Abl: activation and nuclear targets.". Cell death and differentiation 7 (1): 10-6. doi:10.1038/sj.cdd.4400626. PMID 10713716. 
  • Momand J, Wu HH, Dasgupta G (2000). "MDM2--master regulator of the p53 tumor suppressor protein.". Gene 242 (1-2): 15-29. PMID 10721693. 
  • Tortora V, Bontempo P, Verdicchio M, Armetta I, Abbondanza C, Schiavone EM, Nola E, Puca GA, Molinari AM (2000). "Regulation of p53 function in normal and malignant cells.". Advances in experimental medicine and biology 472: 89-100. PMID 10736619. 
  • Hainaut P, Mann K (2002). "Zinc binding and redox control of p53 structure and function.". Antioxidants & redox signaling 3 (4): 611-23. doi:10.1089/15230860152542961. PMID 11554448. 
  • Pearson M, Pelicci PG (2001). "PML interaction with p53 and its role in apoptosis and replicative senescence.". Oncogene 20 (49): 7250-6. doi:10.1038/sj.onc.1204856. PMID 11704853. 
  • Chang NS (2002). "A potential role of p53 and WOX1 in mitochondrial apoptosis (review).". International journal of molecular medicine 9 (1): 19-24. PMID 11744990. 
  • Lopez-Martinez M, Anzola M, Cuevas N, Aguirre JM, De-Pancorbo M (2002). "Clinical applications of the diagnosis of p53 alterations in squamous cell carcinoma of the head and neck.". Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal 7 (2): 108-20. PMID 11887018. 
  • Zupanska A, Kaminska B (2002). "The diversity of p53 mutations among human brain tumors and their functional consequences.". Neurochemistry international 40 (7): 637-45. PMID 11900859. 
  • Nakashima S, Sawada M (2002). "[Involvement of p53 in ceramide signaling cascade]". Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 47 (4 Suppl): 449-54. PMID 11915341. 
  • Alarcon-Vargas D, Ronai Z (2002). "p53-Mdm2--the affair that never ends.". Carcinogenesis 23 (4): 541-7. PMID 11960904. 
  • Le NT, Richardson DR (2002). "The role of iron in cell cycle progression and the proliferation of neoplastic cells.". Biochimica et biophysica acta 1603 (1): 31-46. PMID 12242109. 
  • El-Deiry WS (2003). "Transactivation of repair genes by BRCA1.". Cancer biology & therapy 1 (5): 490-1. PMID 12496474. 
  • Michael D, Oren M (2003). "The p53-Mdm2 module and the ubiquitin system.". Seminars in cancer biology 13 (1): 49-58. PMID 12507556. 
  • Greenway AL, Holloway G, McPhee DA, Ellis P, Cornall A, Lidman M (2004). "HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication.". Journal of biosciences 28 (3): 323-35. PMID 12734410. 
  • Horiike S, Kita-Sasai Y, Nakao M, Taniwaki M (2003). "Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.". Leukemia & lymphoma 44 (6): 915-22. PMID 12854888. 
  • Hartman AR, Ford JM (2004). "BRCA1 and p53: compensatory roles in DNA repair.". Journal of molecular medicine (Berlin, Germany) 81 (11): 700-7. doi:10.1007/s00109-003-0477-0. PMID 13679996. 
  • Vecil GG, Lang FF (2004). "Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses.". Journal of neuro-oncology 65 (3): 237-46. PMID 14682374. 
  • Tolstrup M, Ostergaard L, Laursen AL, Pedersen SF, Duch M (2004). "HIV/SIV escape from immune surveillance: focus on Nef.". Current HIV research 2 (2): 141-51. PMID 15078178. 
  • Hofseth LJ, Hussain SP, Harris CC (2004). "p53: 25 years after its discovery.". Trends in pharmacological sciences 25 (4): 177-81. PMID 15116721. 
  • Amini S, Khalili K, Sawaya BE (2004). "Effect of HIV-1 Vpr on cell cycle regulators.". DNA and cell biology 23 (4): 249-60. doi:10.1089/104454904773819833. PMID 15142382. 
  • Halazonetis TD (2005). "Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer.". DNA repair 3 (8-9): 1057-62. doi:10.1016/j.dnarep.2004.03.036. PMID 15279793. 
  • Selivanova G (2005). "p53: fighting cancer.". Current cancer drug targets 4 (5): 385-402. PMID 15320716. 
  • Seelamgari A, Maddukuri A, Berro R, de la Fuente C, Kehn K, Deng L, Dadgar S, Bottazzi ME, Ghedin E, Pumfery A, Kashanchi F (2006). "Role of viral regulatory and accessory proteins in HIV-1 replication.". Frontiers in bioscience : a journal and virtual library 9: 2388-413. PMID 15353294. 
  • Jacobs WB, Walsh GS, Miller FD (2005). "Neuronal survival and p73/p63/p53: a family affair.". The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry 10 (5): 443-55. doi:10.1177/1073858404263456. PMID 15359011. 
  • Bode AM, Dong Z (2004). "Post-translational modification of p53 in tumorigenesis.". Nature reviews. Cancer 4 (10): 793-805. doi:10.1038/nrc1455. PMID 15510160. 
  • Pise-Masison CA, Brady JN (2006). "Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function.". Frontiers in bioscience : a journal and virtual library 10: 919-30. PMID 15569630. 
  • Xu Y (2006). "A new role for p53 in maintaining genetic stability in embryonic stem cells.". Cell cycle (Georgetown, Tex.) 4 (3): 363-4. PMID 15701975. 
  • Ho JW, Song JZ, Leung YK (2005). "Activation of p53 by specific agents in potential cancer therapy.". Current medicinal chemistry. Anti-cancer agents 5 (2): 131-5. PMID 15777220. 
  • Duensing A, Duensing S (2005). "Guilt by association? p53 and the development of aneuploidy in cancer.". Biochemical and biophysical research communications 331 (3): 694-700. doi:10.1016/j.bbrc.2005.03.157. PMID 15865924. 
  • Castedo M, Perfettini JL, Piacentini M, Kroemer G (2005). "p53-A pro-apoptotic signal transducer involved in AIDS.". Biochemical and biophysical research communications 331 (3): 701-6. doi:10.1016/j.bbrc.2005.03.188. PMID 15865925. 
  • Asher G, Shaul Y (2006). "p53 proteasomal degradation: poly-ubiquitination is not the whole story.". Cell cycle (Georgetown, Tex.) 4 (8): 1015-8. PMID 16082197. 
  • Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG (2006). "ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.". Cell cycle (Georgetown, Tex.) 4 (9): 1166-70. PMID 16082221. 
  • Pise-Masison CA, Jeong SJ, Brady JN (2005). "Human T cell leukemia virus type 1: the role of Tax in leukemogenesis.". Archivum immunologiae et therapiae experimentalis 53 (4): 283-96. PMID 16088313. 
  • Lacroix M, Toillon RA, Leclercq G (2006). "p53 and breast cancer, an update.". Endocrine-related cancer 13 (2): 293-325. doi:10.1677/erc.1.01172. PMID 16728565. 
  • Matsumoto M, Furihata M, Ohtsuki Y (2006). "Posttranslational phosphorylation of mutant p53 protein in tumor development.". Medical molecular morphology 39 (2): 79-87. doi:10.1007/s00795-006-0320-0. PMID 16821145. 
  • Liebermann DA, Hoffman B, Vesely D (2007). "p53 induced growth arrest versus apoptosis and its modulation by survival cytokines.". Cell cycle (Georgetown, Tex.) 6 (2): 166-70. PMID 17264673. 
  • Huang CL, Yokomise H, Miyatake A (2007). "Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers.". Future oncology (London, England) 3 (1): 83-93. doi:10.2217/14796694.3.1.83. PMID 17280505. 
  • Soussi T (2007). "p53 alterations in human cancer: more questions than answers.". Oncogene 26 (15): 2145-56. doi:10.1038/sj.onc.1210280. PMID 17401423. 
  • Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007). "TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.". Oncogene 26 (15): 2157-65. doi:10.1038/sj.onc.1210302. PMID 17401424. 
  • Hussain SP, Schwank J, Staib F, Wang XW, Harris CC (2007). "TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.". Oncogene 26 (15): 2166-76. doi:10.1038/sj.onc.1210279. PMID 17401425. 
  • Kim E, Deppert W (2007). "Interactions of mutant p53 with DNA: guilt by association.". Oncogene 26 (15): 2185-90. doi:10.1038/sj.onc.1210312. PMID 17401427. 
  • Menendez D, Inga A, Jordan JJ, Resnick MA (2007). "Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson.". Oncogene 26 (15): 2191-201. doi:10.1038/sj.onc.1210277. PMID 17401428. 
  • Weisz L, Oren M, Rotter V (2007). "Transcription regulation by mutant p53.". Oncogene 26 (15): 2202-11. doi:10.1038/sj.onc.1210294. PMID 17401429. 
  • Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G (2007). "Mutant p53: an oncogenic transcription factor.". Oncogene 26 (15): 2212-9. doi:10.1038/sj.onc.1210296. PMID 17401430. 
  • Li Y, Prives C (2007). "Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?". Oncogene 26 (15): 2220-5. doi:10.1038/sj.onc.1210311. PMID 17401431. 
  • Joerger AC, Fersht AR (2007). "Structure-function-rescue: the diverse nature of common p53 cancer mutants.". Oncogene 26 (15): 2226-42. doi:10.1038/sj.onc.1210291. PMID 17401432. 
  • Sekine I, Minna JD, Nishio K, Tamura T, Saijo N (2007). "A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer.". Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 1 (1): 31-7. PMID 17409824. 
  • Mellert H, Sykes SM, Murphy ME, McMahon SB (2007). "The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain.". Cell cycle (Georgetown, Tex.) 6 (11): 1304-6. PMID 17534149.